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Abstract
Background: Dementia in Parkinson’s disease (PD) is defined as cognitive decline severe enough to affect activities
of daily living function (ADL). The aim of our exploratory study was to compare two groups of PD patients. Both
groups had cognitive deficits severe enough to justify diagnosis of dementia, but they differed according to
caregivers’ rating on ADL dysfunction. Parameters which differed between the two groups were interpreted to affect
the caregivers’ perception of ADL dysfunction in PD patients with cognitive impairment indicative of Parkinson’s
disease dementia.
Methodology/Principal Findings: Thirty of 131 Parkinson’s disease patients fulfilled the Movement Disorders
Society Task Force – recommended, cognitive Level-I-criteria for dementia. According to standardized caregiver
ratings, volunteers were grouped into 18 patients with (ADL-) and 12 without instrumental activities of daily living
dysfunction (ADL+). Caregiver activities of daily living function ratings closely correlated with self-estimates of
patients and those of physician (p<0.001). ADL- patients performed worse on tests assessing visual-construction
(p<0.05) and attention (p=0.03) than ADL+ patients. Moreover, the postural instability and gait disorder subtype was
more frequent in ADL- patients (p=0.009). ADL- patients tended to have more communication problems (p=0.05),
more anxiety (p=0.05) and showed a tendency to be treated more often with neuroleptics (p=0.049) than ADL+.
Conclusions/Significance: Results indicate that worse attention, visual-construction abilities, the postural instability
and gait disorder subtype, communication problems, medication and presence of anxiety are related to activities of
daily living dysfunctions in Parkinson’s disease patients with cognitive decline indicative of dementia. Our data
suggests that not only cognitive factors but also non-cognitive factors seem to be linked to the diagnosis of
Parkinson’s disease dementia associated with significant impact on instrumental activities of daily living function.
Further studies with larger sample sizes are needed to verify our results.
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Introduction
Dementia is a frequent and disabling condition of idiopathic
Parkinson’s disease (PD), affecting more than 80% of patients
in advanced disease stages [1,2]. For diagnosis and treatment
two clinical requirements are mandatory: significant cognitive
impairment as defined e.g. by the Level-I criteria for probable
Parkinson’s disease dementia (PDD) [3,4], and marked impact
of cognitive dysfunction on Activities of Daily Living (ADL)
functions.
To date, minor cognitive dysfunction is the most common
factor identified in various studies predicting PDD in the near
future [2,5]. However, in early disease stages it is difficult to
distinguish whether cognitive symptoms are a sign of later
dementia or not. Indeed, cognitive worsening can also be found
in PD patients who might not develop PDD [6]. A detailed ADL
evaluation that detects relevant impairment is thus the most
important part of the (differential) diagnosis of PDD. For an
early detection of patients at risk for PDD it might therefore be
helpful to identify, which clinical symptoms accompany
cognitively driven worsening of ADL function.
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Information from caregivers about the patient’s behavior is
often supposed to estimate the patient’s ADL function.
However, evaluation of ADL dysfunction in PD is a challenging
procedure as rater-specific aspects or non-cognitive factors
can interfere with it [7–11]. Regarding the obvious impact of
caregiver ratings on the ADL assessment of physicians, it is
surprising that only few studies have addressed their accuracy
so far [12–14]. Moreover, little is known about clinical signs and
symptoms of PD patients, which most closely relate to
caregiver ratings on cognitively driven ADL impairment.
Previous results show that reduced attention is one of the
strongest predictors for proxy reports on ADL dysfunction in
patients already diagnosed with PDD [15].
Using a comprehensive test battery, we compared the
clinical profile of 30 PD out of 131 patients who (i) had
cognitive impairment indicative of probable PDD as identified
by the Level-I screening procedure of the Movement Disorder
Task Force (MDS-TF) [3,4] and (ii) were rated by their
caregivers as having an ADL impairment (ADL-) or not (ADL+).
The aim of this exploratory study was to identify clinical
parameters which differentiate between the two PD groups,
which might help the clinician to make the diagnosis of PDD.
Both groups had cognitive deficits severe enough to justify
diagnosis of PDD, but they differed according to the caregivers’
rating on ADL dysfunction. Parameters which differed between
the two groups were interpreted to affect the caregivers’
perception of ADL dysfunction in PD patients with cognitive
impairment indicative of PDD.
Materials and Methods
Patients
We recruited a clinical sample of 131 patients with PD
according to the United Kingdom Brain Bank (UKBB) Criteria
[16]. Patients older than 50 years who reported that a caregiver
would be willing to take part in the study were considered.
Exclusion criteria were: diagnosis of dementia within the first
year of parkinsonism, other central nervous system disorders,
deep brain stimulation, history of drug or alcohol abuse,
delirium and a Minimental State Examination (MMSE) [17]
score<18 (cognitive testing not feasible, limited capacity to
consent for study participation). Patients with signs of
depression were not excluded as the influence of behavioral
parameters was considered a relevant outcome parameter. All
patients received their usual medication. The local ethical
committee of the University of Tuebingen approved the study
(121/2009BO2). All patients and caregivers gave written
informed consent according to the Declaration of Helsinki.
Classification of cognitive and ADL impairment
To identify patients with a substantial cognitive impairment
indicative of probable PDD, we used the recommended
screening procedure according to the cognitive Level-I
diagnostic criteria of the MDS-TF [4].
First, we identified all patients who had a MMSE score<26 in
addition to a cognitive impairment in at least two of four tasks
defined as follows: (i) ≤3 of 5 points in the MMSE subtracting
serial 7s task (attention), (ii) a verbal fluency performance
(executive function) of z<-1.0 assessed by the German version
of the CERAD (Consortium to Establish a Registry for
Alzheimer's Disease, German version) [18], (iii) subscore = 0 in
the drawing the pentagon task of the MMSE (visuo-
construction); and (iv) ≤2 of 3 points in the 3-Word Recall of the
MMSE (memory performance) (for details see 4). Therefore,
patients’ grouping was based on the MMSE and the verbal
fluency task, but not on further neuropsychological
measurements or scales. Table 1 gives an overview on the
comparison of patients who did not fulfill (n=101, PD non-
demented, PDND) and those who fulfilled these cognitive
Level-I criteria (n=30, Level-I cogn) indicative of PDD.
In a second step, the latter patients were subdivided
according to their caregiver-rated ADL performance. ADL
ratings were based on a widely used German proxy-scale
(Nuernberger-Alters-Alltagsaktivitaeten-Skala, NAB) [19],
assessing instrumental activity of daily living functions. Scores
below z=-1.0 were considered as impaired ADL function
(ADL-).
Neuropsychological, clinical, and behavioral
assessment
The following parameters were assessed to compare the
clinical characteristics of the two study groups:
Neuropsychological test battery.  A comprehensive
neuropsychological test battery comprised numerous
standardized tests on all relevant cognitive functions in PD
such as executive function, memory, visuo-construction and
attention tasks (see Table 1).
The Parkinson Neuropsychometric Dementia Assessment
(PANDA) was used to screen for global cognitive impairment
[20]. The Tower of London test (TL-D) [21] was included to
assess planning ability. The German version of the CERAD
[18] provides tasks on verbal fluency (VF for animals), naming
ability (Boston Naming Test, BNT), word–list memory (WL),
word-list recall after delay (WL-Delay), word-list recognition
(WL-R) and on visuo-construction (Praxis) including a delayed
recall (Praxis-Delay). The Trail Making Test (TMT) A and B,
both part of the CERAD battery, were used to assess
behavioral regulation, motor speed and set shifting [18].
Memory function was further examined by the Logical
Memory I and II of the revised Wechsler Memory Scale [22].
Working memory capacity was evaluated by using the digit
span part (DS), including both forward and backward recall, of
the NAI (Nuernberger Alters-Inventory) [19]. The Figure Test
(FT) [19] of the NAI was used to assess visual memory
function.
The object decision part of the Visual Object and Space
Perception Battery (VOSP) [23] provides an assessment of
visual function. The ideomotor part of the Berlin-Apraxia-Test
(BAXT) [24] was used to quantify ideomotor apraxia.
Attentional processes were recorded by two subtests of the
computerized version of the TAP “Test for Attentional
Performance” [25]. The subtest “alertness” consists of a single
visual reaction time task (Alertness no cue) and an acoustic
cued condition (Alertness with cue). The subtest “Go-Nogo”
provides a test on selective attention.
Impact on ADL Dysfunction in PD
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Table 1. Neuropsychological performance of patients who
did not fulfill (n=101, PD non-demented, PDND) and those
who fulfilled the cognitive Level-I criteria (n=30, Level-I
cogn.) indicative of PDD.
   
No cognitive
impairment  
Cognitive
impairment
indicating
PDD  
   
PD non
demented
(PDND)
 Level-I-cogn.
PDND
vs.
Level-I-
cogn.
  n values n values p-corrected*
Minimental
State
Examination
screening 101 28 (23-30) 30 24 (15-25) <0.001
PANDA screening 100 21 (10-30) 27 10 (4-26) <0.001
Tower of
London
problem
solving 101 38 (3-99) 30 7 (0-51) <0.001
Consortium to
Establish a
Registry for
Alzheimer's
Disease
      
Verbal fluency wordgeneration 101 34 (0-100) 30 11 (0-90) 0.01
Boston
Naming Test naming 101 50 (1-96) 30 6.5 (0-95) 0.001
Word-list
memory memory 101 34 (0-98) 30 3 (0-86) 0.05
Word-list recall memory 101 31 (0-99) 30 12.5 (0-86) 0.015
Word-list
recognition memory 101 34 (0-86) 30 11 (0-92) 0.005
Word-list
intrusion memory 101 69 (0-79) 30 3 (0-84) 0.005
Praxis visuo-construction 101 38 (0-95) 30 1.5 (0-86) <0.001
Praxis-Delay
visuo-
contruction/
memory
101 21 (0-97) 30 1 (0-84) 0.003
Trail Making
Test, Part A
psychomotor
speed 101 62 (1-100) 30 1.5 (0-62) <0.001
Trail Making
Test, Part B set shifting 101 73 (0-100) 30 0 (0-66) <0.001
Wechsler
Memory Scale
Revised
      
Logical
Memory I memory 101 22 (1-98) 30 3 (1-70) 0.04
Logical
Memory II memory 101 22 (0-92) 30 3.5 (0-68) 0.08
Nuernberger-
Alters-
Inventory
      
Digit span memory 101 65 (4-100) 30 27 (4-100) 0.001
In both, the BAXT and the TAP, patients were instructed to
take the dominant arm or the side with less parkinsonian signs.
Analyses are based on standard norms (percentile rank
scores) of healthy German control subjects as published in the
manuals. Data are corrected either for age (NAI, WMS-R,
VOSP) or for age and education (CERAD, TAP, TMT-A, TMT-
B, TL-D; please compare [26]).
Neurological scales
Neurological evaluation included the Unified Parkinson’s
Disease Rating Scale (UPDRS) part III [27], the Hoehn and
Yahr (H&Y) scale [28] and the Schwab and England Activities
of Daily Living Scale (S&E-ADL) [29]. Based on the UPDRS
scores, patients’ were assigned to one of three different motor
types: the postural instability and gait disorder (PIGD), the
tremor-dominant, or the indeterminate subtype [30,31].
Levodopa equivalent dose (LEDD) was calculated using the
following conversion factors: 100 mg levodopa equaled 125 mg
levodopa sustained release, 1mg pergolide, 1mg pramipexol, 5
mg ropinirole, 5 mg rotigotin, 10 mg bromocriptine, 10 mg
Table 1 (continued).
   
No cognitive
impairment  
Cognitive
impairment
indicating
PDD  
Figure Test visuo-spatial/memory 101 65 (4-95) 30 14 (0-88) 0.001
Visual Object
and Space
Perception
Battery
      
Object
decision visuo-spatial 101
38.1
(3.6-100) 30
11.9
(2.4-100) 0.02
Berlin Apraxia
Test
praxis/
executive
function
101 39 (27-44) 30 30.5(17-39) 0.001
Test for
Attentional
Performance
      
Alertness-no
cue, Median
attention/
alertness 98 12 (0-79) 28 2 (0-50) 0.001
Alertness-with
cue, Median
attention/
alertness 98 14 (0-82) 28 2.5 (0-50) 0.001
Go-Nogo,
Median
directed
attention 101 54 (0-100) 29 4 (0-66) 0.001
Values are given as median and range (minimum-maximum). *P-values are
corrected for age and motor performance according to the Unified Parkinson’s
Disease Rating Scale Part III by using multivariate regression analysis. Mean
group performances are given in relation to the standardized values provided by
the test manuals with lower values indicating poorer test performances. Only for
the Berlin Apraxia Test raw data are presented. ADL: Activities of Daily Living.;
PANDA: Parkinson Neuropsychometric Dementia Assessment; PD: Parkinson's
Disease; PDD: Parkinson's Disease Dementia; p: Level of significance; N: number.
doi: 10.1371/journal.pone.0082902.t001
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apomorphine, 1/5 entacapone, and 1.5 mg cabergoline.
Additionally, 5% was added to the total levodopa dose for
every 5 mg of selegiline or 1 mg of rasagiline, up to a maximum
of 10%; [32–34].
Neurobehavioral assessment.  We applied the Beck-
Depression Inventory (BDI), which provides a self-rating scale
for symptoms associated with depression. A value ≥18
indicates a major depression [35]. The additionally used
Parkinson’s Disease Questionnaire (PDQ-39) [36] evaluates
eight aspects of patients’ perceived health-related quality of life
(HRQoL), i.e. mobility, ADL, emotions, stigma, social,
cognitions, communication and body pain. Moreover, the
Neuropsychiatric Inventory (NPI) [37] was used to evaluate ten
neurobehavioral domains (e.g. delusions, hallucinations,
depression or apathy). Corresponding to the NAB proxy scale,
patients’ self-estimated ADL function was assessed by a
standardized questionnaire (Nuernberger-Alters-
Alltagsaktivitaeten-Skala, NAA) [19].
Statistical Analyses
As data were not normally distributed, the data analysis was
based on non-parametric statistics. For validation purposes
(e.g. to prove clear differences in cognitive impairment),
analyses between the PDND (n=101) and the total group of
patients who met the Level-I-cogn criteria (n=30) were
calculated. Linear regression analysis was used, with the
parameters of interest included into the model as predictors
and the group-membership (PDND vs. Level-I cogn criteria
binary coded), age and UPDRS-III motor score included as
independent variables. Disease duration was not included in
the regression model, as it was highly correlated with the
UPDRS-III score.
Statistical mean group comparisons between the ADL- and
ADL+ groups were performed with either the Mann-Whitney-U
or the Fisher’s exact test. Due to the exploratory nature the
significance level was set at p<0.05 (two-sided). All analyses
were done with IBM SPSS Statistics 19.0 for Windows.
Results
Thirty of 131 PD patients (22.9%) fulfilled the Level-I criteria
for the classification of cognitive impairment indicative of PDD.
Of those, 12 were classified as ADL+ and 18 as ADL-. For
validation purposes, the proxy reports on severity of ADL
impairment were compared to ratings of physician and patients
self-estimates. The NAB scale correlated well with evaluations
of physicians (S&E-ADL p<0.001) and the patient’s NAA score
(NAA p<0.001).
Missing Values
The PANDA was not performed in six patients (n=3 PDND,
n=2 ADL+ and n=1 ADL-) due to reduced compliance and/or
severity of cognitive impairment. Missing data in the two
subtests of the TAP was due to technical problems (e.g. data
saving errors). One patient in of the ADL- group refused to
complete the BDI.
PDND versus Level-I-cogn total
Patients who fulfilled the Level-I-cogn criteria were
significantly more impaired than the PDND group in nearly all
neuropsychological tasks (all p values ≤0.05 corrected for age
and motor performance, see Table 1 for details). These results
strongly indicate that patients who met the cognitive MDS-TF
screening criteria indeed suffer from a substantial cognitive
impairment suggesting probable PDD. No significant
differences (p>0.05) were found between the groups with
regard to gender (60.4%), level of education (12 years, 8-19),
and levodopa equivalence dose (504, 0-2030). The PDND
group was younger (67.0 years, 51-85; p<.001), had a shorter
disease duration (4.0 year, 0.3-19; p<.001) and lesser motor
impairment according to the UPDRS-III (24.0 points, 7-62; p<.
0.001) compared to the Level-I- cogn group.
ADL- vs. ADL+
Almost all patients (17 out of 18) who met the Level-I-cogn
criteria and were ADL- belonged to the PIGD subtype (see
Table 2). In comparison, only 50% of the ADL+ group were
PIGD (p=0.009). Our neuropsychological assessment revealed
that ADL- patients performed worse on neuropsychological
tests assessing visuo-construction (p<0.05) and attention
(p=0.03, Table 3).
There was a tendency for ADL- patients to be rated as more
anxious by the caregivers (NPI-subscale-E: ADL-, median=0,
range=0-8; ADL+, median=0, range=0-1; p=0.05) than ADL+
patients. They reported themselves as being slightly more
impaired in ADL function (PDQ-scale 2: 62.5, 4.2-91.7, ADL+,
29.2, 0-100; p=0.03) and tended to have more severe
communication problems (PDQ-39-communication: ADL-, 41.7,
0-66.7; ADL+, 25, 0-75; p=0.05) than the ADL+ group. ADL-
patients received neuroleptics more often compared to patients
with ADL+ (p=0.049), however this effect was statistically
borderline.
Even if the frequency of patients with major depression did
not differ between the two groups (p=1.00), severity of
depression might have affected the interpretation of the
neuropsychological data. Therefore, analysis of the
neuropsychological data was replicated after excluding patients
with major depression (n=2, ADL+; n=4, ADL-) or undefined
status of depression (n=1, ADL-). Except for the Go-Nogo TAP
task assessing attention (p=0.06, see Table S1 for details)
differences in the PANDA (p=0.01) and in tasks measuring
visuo-construction (p<0.05) reach statistical significance.
Discussion
According to the MDS-TF criteria [3,4], significant impairment
of ADL function is the core criterion for differentiating PDND
from PDD. We investigated which clinical (including cognitive)
factors contribute to the caregiver’s rating of significant ADL
dysfunction in PD patients. Following the recommended Level I
criteria of the MDS-TF, we selected a patients group with
cognitive impairment indicative of PDD [4]. In our sample,
22.9% of PD patients met the cognitive requirements for
diagnosis of PDD according to the consensus guidelines,
resembling previous data [38]. The selection of the Level-I-
Impact on ADL Dysfunction in PD
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cogn group was primarily based on the MMSE and the verbal
fluency tasks. Neuropsychological test data verified that PD
Table 2. Clinical data of patients with cognitive performance
indicating PDD who were rated by rated by their caregivers
as having an ADL impairment (ADL-) or not (ADL+).
  
No ADL
impairment
(ADL+)  
ADLimpairment
(ADL-)
ADL
+vs.ADL-
 n values n values p
Demographics      
Age at evaluation
(years) 12 71.5 (63-85) 18 74 (64-86) 0.54
Male gender [N (%)] 12 9 (75.0) 18 14 (77.8) 1.00
Years of disease
duration 12 7.5 (2-16) 18 10.5 (4-24) 0.09
Years of education 12 11 (8-20) 18 11 (8-17) 0.87
Motor assessment      
UPDRS-III 12 35.5 (19-57) 18 39.5 (28-60) 0.11
Hoehn & Yahr stages
[N (%)] 12  18   
1
1.5  
2 (16.7)
0 (0)  
0 (0)
0 (0) 0.40
2
2.5  
2 (16.7)
2 (16.7)  
4 (22.2)
1 (5.6)  
3
4  
3 (25.0)
3 (25.0)  
7 (38.9)
6 (33.3)  
Schwab & England
Scale 12 80 (50-100) 18 60 (10-80) 0.005
Motor Type 12  18   
Tremor-dominant [N
(%)]  3 (25.0)  0 0.009
PIGD [N (%)]  6 (50.0)  17 (94.4)  
Indeterminate [N (%)]  3 (25.0)  1 (5.6)  
Medication      
Levodopa
equivalence dose
(mg)
12 450(66.7-1360) 18
726.5
(100-1582.5) 0.22
Monotherapy with L-
Dopa [N (%)]  4 (33.3)  5 (27.8) 0.047
Monotherapy with
Dopamin-Agonists [N
(%)]
 3 (25.0)  0  
L-Dopa and
Dopaagonists [N (%)]  5 (41.7)  13 (72.2)  
Other PD medication
[N (%)]  0  0  
Antidepressants [N
(%)] 12 1 (8.3) 18 5 (27.8) 0.36
Neuroleptics [N (%)] 12 1 (8.3) 18 8 (44.4) 0.049
Antidementiva [N (%)] 12 2 (16.7) 18 6 (33.3) 0.42
Depression      
Becks Depression
Inventory 12 11.5 (0-34) 17 14 (1-39) 0.40
Major depression [N
(%)] 12 2 (16.7) 17 4 (23.5) 1.00
patients who fulfilled the Level-I-cogn criteria were indeed
cognitively more severely impaired than PD patients who did
not meet these criteria. This further supports the usefulness of
the proposed criteria. Moreover, in line with previous studies
[39–41], cognitive dysfunction was associated with older age,
longer disease duration and behavioral abnormalities.
The main focus of this study was to compare the cognitive,
neurobehavioral and motor characteristics of PD patients with
cognitive impairment according to the Level-I-cogn criteria that
were either judged by their caregivers as having (ADL-) or not
having (ADL+) ADL impairment. ADL+ and ADL- patients
differed in various aspects, namely in neuropsychological
performance, motor type, communication problems, and
medication. In our study, caregiver ratings closely correlated
with self-estimates of PD patients and those of physician. This
argues for the validity of the observation and judgment of
proxies. Therefore, we suggest that standardized caregiver
ratings as used in this study can contribute to the clinical PDD
diagnosis. In fact, two different cognitive phenotypes could be
differentiated within our patient group with substantial cognitive
impairment.
Performances in attention and visuo-construction tasks were
strongly related to the caregivers’ ADL ratings and therefore
more pronounced in the ADL- group. These results fit well with
previous work. Reduced attention in PD patients is one of the
strongest predictors for the severity of caregiver rated ADL
impairment [15]. Moreover, impaired visuo-constructional
abilities can predict future onset of PDD [2,5]. Yet, our data do
not support previous findings of a close relationship between
executive function and ADL function in PD [42,43]. This
discrepancy might partly be explained by different assessments
and recruitment strategies. In contrast to Cahn and colleagues
[42] who explicitly focused on the assessment of executive
function in candidates for pallidotomy, we examined a broad
range of cognitive domains known to be affected in PD in a
sample with a pre-defined cognitive status. Dymek and co-
workers identified executive dysfunction as the main predictor
for loss of capacity to consent to treatment in cognitively
impaired PD patients [44]. In this study, however, we revealed
attention as the main contributor to caregiver`s judgment on
ADL dysfunction. Unlike the work of Dymek and co-workers,
we used subjective proxy statements to define ADL dysfunction
in PD.
With regard to non-cognitive symptoms, our results are
consistent with previous observations that a higher ADL
impairment is more closely related to the PIGD than to the
tremor dominant subtype [45]. It has been demonstrated
Table 2 (continued).
Values are given as median and range (minimum-maximum) unless otherwise
noted. ADL: Activities of Daily Living; N: number; mg: milligram; (%): percentage;
p: Level of significance; PD: Parkinson's Disease; UPDRS-III: Unified Parkinson
Disease Rating Scale Part III; PIGD: phenotype with postural instability and gait
disorders; Indeterminate: phenotype with tremor as well as postural instability and
gait disorders.
doi: 10.1371/journal.pone.0082902.t002
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repeatedly that the risk of PDD is increased in PIGD patients,
particularly in later disease stages, compared to the other
motor subtypes [31,46,47]. Interestingly, in our study, patients
with ADL- were not older and showed only a tendency of longer
disease duration compared to those with ADL+. Nevertheless,
this study adds to the hypothesis that a common or associated
pathological process leads to progressive cognitive decline and
development of PIGD motor type [6,46].
Moreover, we found that ADL- patients reported more
communication problems than ADL+ patients. Speech and
voice difficulties are common in PD patients [48] and are
associated with motor and non-motor symptoms. A self-
perceived negative impact on communication is known to be
related to PD duration [49] and ADL dysfunction [50]. Further, it
is assumed that cortically modulated, executive (dys)function
underlies verb production in PD [51], which itself can alter the
ability to communicate. As mentioned before, ADL- and ADL+
patients did not differ according to their executive function, but
rather in attention. Based on our data we can only speculate
that there might also be a link between attention and
communication problems or the speech process.
Almost two thirds of our patients with ADL- were treated with
both levodopa and dopaminergic agonists, which revealed a
tendency to be taken more often than in ADL+ patients.
Table 3. Neuropsychological performance of patients with cognitive performance indicating PDD who were rated by rated by
their caregivers as having an ADL impairment (ADL-) or not (ADL+).
   No cognitive impairment 
Cognitive impairment
indicating PDD  
Cognitive impairment
indicating PDD  
   PD non demented(PDND)  
No ADL impairment
(ADL+)  
ADL
impairment (ADL-)
ADL+
vs.
ADL-
  n values n values n values p
Minimental State Examination screening 101 28 (23-30) 12 24 (19-25) 18 24 (15-25) 0.47
PANDA screening 100 21 (10-30) 10 17.50 (9-26) 17 9.00 (4-18) 0.002
Tower of London problem solving 101 38 (3-99) 12 10 (0-35) 18 3 (0-51) 0.09
Consortium to Establish a Registry
for Alzheimer's Disease         
Verbal fluency word generation 101 34 (0-100) 12 4.5 (0-76) 18 16 (0-90) 0.16
Boston Naming Test naming 101 50 (1-96) 12 4 (0-76) 18 9 (0-95) 0.23
Word-list memory memory 101 34 (0-98) 12 5.5 (0-42) 18 3 (0-86) 0.65
Word-list recall memory 101 31 (0-99) 12 21 (0-86) 18 7.5 (0-69) 0.47
Word-list recognition memory 101 34 (0-86) 12 3.5 (0-92) 18 12 (0-86) 0.29
Word-list intrusion memory 101 69 (0-79) 12 3.0 (0-84) 18 3 (0-82) 0.83
Praxis visuo-construction 101 38 (0-95) 12 2.5 (0-86) 18 0 (0-82) 0.05
Praxis-Delay visuo-contruction/memory 101 21 (0-97) 12 15 (0-84) 18 0 (0-13) 0.001
Trail Making Test, Part A psychomotor speed 101 62 (1-100) 12 1.5 (0-62) 18 1.5 (0-58) 0.52
Trail Making Test, Part B set shifting 101 73 (0-100) 12 0 (0-58) 18 0 (0-66) 0.83
Wechsler Memory Scale Revised         
Logical Memory I memory 101 22 (1-98) 12 3 (1-23) 18 3 (1-70) 0.63
Logical Memory II memory 101 22 (0-92) 12 4 (0-47) 18 3.5 (0-68) 0.99
Nuernberger-Alters-Inventory         
Digit span memory 101 65 (4-100) 12 27 (4-65) 18 31.5 (4-100) 0.48
Figure Test visuo-spatial/memory 101 65 (4-95) 12 20.5 (0-82) 18 10 (0-88) 0.28
Visual Object and Space
Perception Battery         
Object decision visuo-spatial 101 38.1 (3.6-100) 12 34.6 (3.6-100) 18 9.5 (2.4-47.6) 0.08
Berlin Apraxia Test praxis/executivefunction 101 39 (27-44) 12 29.5 (21-38) 18 32.5 (17-39) 0.33
Test for Attentional Performance         
Alertness-no cue, Median attention/alertness 98 12 (0-79) 11 3 (0-46) 17 2 (0-50) 0.17
Alertness-with cue, Median attention/alertness 98 14 (0-82) 11 4 (0-50) 17 2 (0-31) 0.75
Go-Nogo, Median directed attention 101 54 (0-100) 11 10 (0-66) 18 1.5 (0-54) 0.03
Values are given as median and range (minimum-maximum). Mean group performances are given in relation to the standardized values provided by the test manuals with
lower values indicating poorer test performances. Only for the Berlin Apraxia Test raw data are presented. ADL: Activities of Daily Living.; PANDA: Parkinson
Neuropsychometric Dementia Assessment; PD: Parkinson's Disease; PDD: Parkinson's Disease Dementia; p: Level of significance; N: number.
doi: 10.1371/journal.pone.0082902.t003
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However interpretation of this effect is limited by the sample
size of our cohort. One might speculate that the association of
the PIGD subtype with ADL impairment in our cohort explains
this effect.
This is also interesting in the light of existing evidence that
PDD patients are more prone to hallucinations and psychosis
than PD patients without dementia [52]. Moreover, if these
symptoms occur, they are primarily treated with antipsychotics.
This might explain our finding that ADL- patients receive such
drugs more often although the difference of hallucination
frequency between the groups was not statistically significant.
Limitations
The present study applied the MDS-TF Level-I screening
procedure to define cognitive impairment indicative of PDD [4].
Specificity of this approach is high, however sensitivity may be
lower [12,38,41,53]. For the sake of high diagnostic specificity,
it could therefore be the case that we did not include all PD
patients showing a substantial cognitive impairment. We
cannot exclude the fact that caregivers might not be able to
detect slight progressive changes in patients ADL function at
home, especially if they are masked by accompanying motor or
other non-cognitive symptoms (e.g. autonomic failure or
psychiatric abnormalities) [8,54]. It is also possible that these
conflicting factors modulated the standardized caregiver ADL
ratings.
Moreover, our conclusions based on a group of 30 patients
who fulfilled the Level-I-cogn criteria are limited by the sample
size and the exploratory nature of the study. Further studies
with larger sample sizes are needed to verify our results.
In contrast to the recommendation of the MDS-TF, patients
with major depression were not excluded. We argue that
depression affects about 35 percent of PD patients and can
influence both, cognitive performance and ADL function
[55,56].
Therefore, in patients with confirmed major depression, a
PDD diagnosis is a possibility [3,4] as discussed in recent
validation studies [12,38]. During their daily routine, clinicians
are often faced with this co-morbidity, particularly because the
frequency of both conditions increase with disease duration
[1,57]. Moreover, patients with depression were included in this
study, as it presents a possible risk marker for PDD. The
occurrence and frequency of depression has been shown to be
associated to faster cognitive decline [58]. In our sample the
ADL+ and ADL- group did not statistically differ in the BDI total
score. Thus, we conclude that that the severity of depression
does not have an major effect on caregiver–rated ADL
(dys)function as assessed in this study.
Conclusions
Caregiver ADL ratings corresponded well with the self-
impression of PD patients and ratings of physician. This
supports the validity of the observation and judgment of
proxies. Moreover, caregiver ADL ratings were found to be
associated with attention, but also with other symptoms such
as PIGD subtype, communication problems and medication in
PD patients with cognitive decline indicative of dementia. Our
data suggests that not only cognitive factors, but also non-
cognitive factors seem to be linked to the diagnosis of PDD
associated with ADL-.
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(ADL+) after the exclusion of patients with major
depression (n=2 ADL+, n=5 ADL-).
Table S1 shows the replication of the main analysis after
excluding patients with major depression (n=2, ADL+; n=4,
ADL-) or undefined status of depression (n=1, ADL-). Values
are given as median and range (minimum-maximum). Mean
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